JP2017501172A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501172A5
JP2017501172A5 JP2016540693A JP2016540693A JP2017501172A5 JP 2017501172 A5 JP2017501172 A5 JP 2017501172A5 JP 2016540693 A JP2016540693 A JP 2016540693A JP 2016540693 A JP2016540693 A JP 2016540693A JP 2017501172 A5 JP2017501172 A5 JP 2017501172A5
Authority
JP
Japan
Prior art keywords
survivin
seq
mol
liposome preparation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/003384 external-priority patent/WO2015090572A1/en
Publication of JP2017501172A publication Critical patent/JP2017501172A/ja
Publication of JP2017501172A5 publication Critical patent/JP2017501172A5/ja
Pending legal-status Critical Current

Links

JP2016540693A 2013-12-16 2014-12-16 サバイビン指向性癌ワクチン治療 Pending JP2017501172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005831 2013-12-16
EP13005831.6 2013-12-16
PCT/EP2014/003384 WO2015090572A1 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Publications (2)

Publication Number Publication Date
JP2017501172A JP2017501172A (ja) 2017-01-12
JP2017501172A5 true JP2017501172A5 (cg-RX-API-DMAC7.html) 2017-12-28

Family

ID=49884863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540693A Pending JP2017501172A (ja) 2013-12-16 2014-12-16 サバイビン指向性癌ワクチン治療

Country Status (8)

Country Link
US (1) US20160279213A1 (cg-RX-API-DMAC7.html)
EP (1) EP3083663A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017501172A (cg-RX-API-DMAC7.html)
CN (1) CN105873941A (cg-RX-API-DMAC7.html)
AU (1) AU2014365888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2933705A1 (cg-RX-API-DMAC7.html)
IL (1) IL246299A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015090572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA2940018C (en) * 2014-02-19 2018-12-04 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
CN109125741B (zh) * 2018-08-13 2022-02-11 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111983240B (zh) * 2020-08-27 2023-11-21 天津大学 一种产气荚膜梭菌α毒素可视化检测的方法
JP7318983B2 (ja) * 2021-12-21 2023-08-01 株式会社アビー 細胞凍結保存液、及び細胞凍結方法
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736587B2 (en) * 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
CN102137675A (zh) * 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答

Similar Documents

Publication Publication Date Title
JP2017501172A5 (cg-RX-API-DMAC7.html)
Ho et al. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?
ES2702622T3 (es) Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
Hartman et al. Increasing vaccine potency through exosome antigen targeting
Vacchelli et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Razazan et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
KR102823291B1 (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
JP2013526837A5 (cg-RX-API-DMAC7.html)
CN108350411B (zh) 口服肿瘤疫苗
Huang et al. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model
Robson et al. Presentation of tumour antigens by dendritic cells and challenges faced
US20160279213A1 (en) Survivin-Directed Cancer Vaccine Therapy
WO2017120576A1 (en) Cancer vaccines and methods of delivery
CN110049774A (zh) 肿瘤相关抗原表位的小型生物群序列变体
CN110621339A (zh) 疫苗接种
JP2010514669A5 (cg-RX-API-DMAC7.html)
CN110022894B (zh) 用于癌症疗法的免疫原性化合物
CN110214028A (zh) 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
Shariat et al. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects
JP2014506114A5 (cg-RX-API-DMAC7.html)
US20240033336A1 (en) Tumor antigens, compounds comprising the tumor antigens and uses thereof
Heurtault et al. Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants
JP2017500305A5 (cg-RX-API-DMAC7.html)
del Carmen Torréns et al. A vaccine candidate against the human papillomavirus: an alternative to treat cervico-uterine tumors
HK1220914B (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer